nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Increased Diuresis—Hydrochlorothiazide—nephrolithiasis	0.449	1	CiPCiCtD
Metolazone—SLC12A3—Hydrochlorothiazide—nephrolithiasis	0.0672	0.269	CbGbCtD
Metolazone—Benzthiazide—Hydrochlorothiazide—nephrolithiasis	0.0631	0.265	CrCrCtD
Metolazone—Quinethazone—Hydrochlorothiazide—nephrolithiasis	0.0631	0.265	CrCrCtD
Metolazone—Methyclothiazide—Hydrochlorothiazide—nephrolithiasis	0.058	0.244	CrCrCtD
Metolazone—Chlorothiazide—Hydrochlorothiazide—nephrolithiasis	0.0537	0.226	CrCrCtD
Metolazone—CA5B—Hydrochlorothiazide—nephrolithiasis	0.0526	0.211	CbGbCtD
Metolazone—CA9—Hydrochlorothiazide—nephrolithiasis	0.0452	0.181	CbGbCtD
Metolazone—CA12—Hydrochlorothiazide—nephrolithiasis	0.0452	0.181	CbGbCtD
Metolazone—CA4—Hydrochlorothiazide—nephrolithiasis	0.0397	0.159	CbGbCtD
Metolazone—SLC12A3—loop of Henle—nephrolithiasis	0.0115	0.441	CbGeAlD
Metolazone—SLC12A3—collecting duct of renal tubule—nephrolithiasis	0.00655	0.251	CbGeAlD
Metolazone—SLC12A3—nephron—nephrolithiasis	0.00292	0.112	CbGeAlD
Metolazone—Angiitis necrotising—Hydrochlorothiazide—nephrolithiasis	0.00266	0.108	CcSEcCtD
Metolazone—Vasculitis necrotising—Hydrochlorothiazide—nephrolithiasis	0.00232	0.0945	CcSEcCtD
Metolazone—CA4—Erythrocytes take up carbon dioxide and release oxygen—AQP1—nephrolithiasis	0.00222	0.178	CbGpPWpGaD
Metolazone—Cutaneous vasculitis—Hydrochlorothiazide—nephrolithiasis	0.00186	0.0759	CcSEcCtD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00085	0.0681	CbGpPWpGaD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.000777	0.0623	CbGpPWpGaD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.000777	0.0623	CbGpPWpGaD
Metolazone—SLC12A3—nephron tubule—nephrolithiasis	0.000629	0.0241	CbGeAlD
Metolazone—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.000599	0.0245	CcSEcCtD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.000589	0.0472	CbGpPWpGaD
Metolazone—CA7—renal system—nephrolithiasis	0.000584	0.0224	CbGeAlD
Metolazone—SLC12A3—renal system—nephrolithiasis	0.000572	0.0219	CbGeAlD
Metolazone—CA7—kidney—nephrolithiasis	0.000565	0.0216	CbGeAlD
Metolazone—SLC12A3—kidney—nephrolithiasis	0.000553	0.0212	CbGeAlD
Metolazone—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.000552	0.0225	CcSEcCtD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.000548	0.0439	CbGpPWpGaD
Metolazone—SLC12A3—cortex of kidney—nephrolithiasis	0.000539	0.0206	CbGeAlD
Metolazone—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.000523	0.0214	CcSEcCtD
Metolazone—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.000523	0.0214	CcSEcCtD
Metolazone—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.000494	0.0202	CcSEcCtD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.000488	0.0391	CbGpPWpGaD
Metolazone—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.000458	0.0187	CcSEcCtD
Metolazone—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.000401	0.0164	CcSEcCtD
Metolazone—Swelling—Hydrochlorothiazide—nephrolithiasis	0.000399	0.0163	CcSEcCtD
Metolazone—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.000394	0.0161	CcSEcCtD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00038	0.0304	CbGpPWpGaD
Metolazone—CA12—renal system—nephrolithiasis	0.000379	0.0145	CbGeAlD
Metolazone—CA12—kidney—nephrolithiasis	0.000367	0.014	CbGeAlD
Metolazone—Purpura—Hydrochlorothiazide—nephrolithiasis	0.000365	0.0149	CcSEcCtD
Metolazone—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.000354	0.0144	CcSEcCtD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000347	0.0278	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000347	0.0278	CbGpPWpGaD
Metolazone—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.000323	0.0132	CcSEcCtD
Metolazone—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.000322	0.0131	CcSEcCtD
Metolazone—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.000321	0.0131	CcSEcCtD
Metolazone—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.000317	0.0129	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.000317	0.0129	CcSEcCtD
Metolazone—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.000306	0.0125	CcSEcCtD
Metolazone—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000298	0.0122	CcSEcCtD
Metolazone—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00028	0.0114	CcSEcCtD
Metolazone—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.000278	0.0113	CcSEcCtD
Metolazone—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.000275	0.0112	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.000269	0.011	CcSEcCtD
Metolazone—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.000266	0.0109	CcSEcCtD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000263	0.0211	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000263	0.0211	CbGpPWpGaD
Metolazone—CA4—nephron tubule—nephrolithiasis	0.000258	0.00989	CbGeAlD
Metolazone—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.000256	0.0105	CcSEcCtD
Metolazone—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.000253	0.0103	CcSEcCtD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000245	0.0196	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000245	0.0196	CbGpPWpGaD
Metolazone—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.000244	0.00995	CcSEcCtD
Metolazone—CA4—renal system—nephrolithiasis	0.000235	0.00899	CbGeAlD
Metolazone—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00023	0.00941	CcSEcCtD
Metolazone—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.000227	0.00927	CcSEcCtD
Metolazone—CA4—kidney—nephrolithiasis	0.000227	0.00869	CbGeAlD
Metolazone—CA4—cortex of kidney—nephrolithiasis	0.000221	0.00847	CbGeAlD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000218	0.0175	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000217	0.0173	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000217	0.0173	CbGpPWpGaD
Metolazone—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000209	0.00853	CcSEcCtD
Metolazone—Tension—Hydrochlorothiazide—nephrolithiasis	0.000208	0.0085	CcSEcCtD
Metolazone—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000208	0.00848	CcSEcCtD
Metolazone—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.000206	0.00841	CcSEcCtD
Metolazone—Back pain—Hydrochlorothiazide—nephrolithiasis	0.000205	0.00838	CcSEcCtD
Metolazone—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.000204	0.00833	CcSEcCtD
Metolazone—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.0002	0.00816	CcSEcCtD
Metolazone—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.000197	0.00803	CcSEcCtD
Metolazone—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000196	0.008	CcSEcCtD
Metolazone—Agitation—Hydrochlorothiazide—nephrolithiasis	0.000195	0.00796	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000193	0.0155	CbGpPWpGaD
Metolazone—Malaise—Hydrochlorothiazide—nephrolithiasis	0.000191	0.00781	CcSEcCtD
Metolazone—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.000191	0.00778	CcSEcCtD
Metolazone—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00019	0.00777	CcSEcCtD
Metolazone—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00019	0.00775	CcSEcCtD
Metolazone—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000187	0.00765	CcSEcCtD
Metolazone—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000186	0.00761	CcSEcCtD
Metolazone—Cough—Hydrochlorothiazide—nephrolithiasis	0.000185	0.00756	CcSEcCtD
Metolazone—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000181	0.00737	CcSEcCtD
Metolazone—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000181	0.00737	CcSEcCtD
Metolazone—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00018	0.00735	CcSEcCtD
Metolazone—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.000178	0.00728	CcSEcCtD
Metolazone—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000177	0.00721	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000177	0.0141	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000177	0.0141	CbGpPWpGaD
Metolazone—Shock—Hydrochlorothiazide—nephrolithiasis	0.00017	0.00695	CcSEcCtD
Metolazone—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.000169	0.00692	CcSEcCtD
Metolazone—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000165	0.00674	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000158	0.00644	CcSEcCtD
Metolazone—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000157	0.00639	CcSEcCtD
Metolazone—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000155	0.00635	CcSEcCtD
Metolazone—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000154	0.00628	CcSEcCtD
Metolazone—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000152	0.00622	CcSEcCtD
Metolazone—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00015	0.00614	CcSEcCtD
Metolazone—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000149	0.00609	CcSEcCtD
Metolazone—Pain—Hydrochlorothiazide—nephrolithiasis	0.000148	0.00604	CcSEcCtD
Metolazone—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000148	0.00604	CcSEcCtD
Metolazone—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000143	0.00582	CcSEcCtD
Metolazone—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000142	0.00578	CcSEcCtD
Metolazone—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000138	0.00561	CcSEcCtD
Metolazone—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000137	0.00559	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000134	0.0107	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000134	0.0107	CbGpPWpGaD
Metolazone—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000128	0.00521	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000124	0.00996	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000124	0.00996	CbGpPWpGaD
Metolazone—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000124	0.00507	CcSEcCtD
Metolazone—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000122	0.005	CcSEcCtD
Metolazone—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000118	0.00484	CcSEcCtD
Metolazone—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000114	0.00467	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000111	0.00888	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000111	0.00888	CbGpPWpGaD
Metolazone—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00011	0.00449	CcSEcCtD
Metolazone—Rash—Hydrochlorothiazide—nephrolithiasis	0.000109	0.00446	CcSEcCtD
Metolazone—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000109	0.00445	CcSEcCtD
Metolazone—Headache—Hydrochlorothiazide—nephrolithiasis	0.000108	0.00443	CcSEcCtD
Metolazone—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000103	0.0042	CcSEcCtD
Metolazone—CA5A—Metabolism—GRHPR—nephrolithiasis	9.61e-05	0.0077	CbGpPWpGaD
Metolazone—CA7—Metabolism—GRHPR—nephrolithiasis	8.98e-05	0.00719	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GRHPR—nephrolithiasis	8.98e-05	0.00719	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	8.86e-05	0.0071	CbGpPWpGaD
Metolazone—CA5A—Metabolism—AGXT—nephrolithiasis	8.57e-05	0.00686	CbGpPWpGaD
Metolazone—CA12—Metabolism—GRHPR—nephrolithiasis	8.31e-05	0.00666	CbGpPWpGaD
Metolazone—CA7—Metabolism—AGXT—nephrolithiasis	8e-05	0.00641	CbGpPWpGaD
Metolazone—CA5B—Metabolism—AGXT—nephrolithiasis	8e-05	0.00641	CbGpPWpGaD
Metolazone—CA12—Metabolism—AGXT—nephrolithiasis	7.41e-05	0.00594	CbGpPWpGaD
Metolazone—CA5A—Metabolism—APRT—nephrolithiasis	7.29e-05	0.00584	CbGpPWpGaD
Metolazone—CA5A—Metabolism—SLC26A1—nephrolithiasis	7.29e-05	0.00584	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SLC26A1—nephrolithiasis	6.8e-05	0.00545	CbGpPWpGaD
Metolazone—CA7—Metabolism—APRT—nephrolithiasis	6.8e-05	0.00545	CbGpPWpGaD
Metolazone—CA5B—Metabolism—APRT—nephrolithiasis	6.8e-05	0.00545	CbGpPWpGaD
Metolazone—CA7—Metabolism—SLC26A1—nephrolithiasis	6.8e-05	0.00545	CbGpPWpGaD
Metolazone—CA4—Metabolism—GRHPR—nephrolithiasis	6.63e-05	0.00531	CbGpPWpGaD
Metolazone—CA12—Metabolism—APRT—nephrolithiasis	6.3e-05	0.00505	CbGpPWpGaD
Metolazone—CA12—Metabolism—SLC26A1—nephrolithiasis	6.3e-05	0.00505	CbGpPWpGaD
Metolazone—CA4—Metabolism—AGXT—nephrolithiasis	5.91e-05	0.00473	CbGpPWpGaD
Metolazone—CA9—Metabolism—GRHPR—nephrolithiasis	5.36e-05	0.00429	CbGpPWpGaD
Metolazone—CA5A—Metabolism—AQP1—nephrolithiasis	5.19e-05	0.00416	CbGpPWpGaD
Metolazone—CA4—Metabolism—SLC26A1—nephrolithiasis	5.03e-05	0.00402	CbGpPWpGaD
Metolazone—CA4—Metabolism—APRT—nephrolithiasis	5.03e-05	0.00402	CbGpPWpGaD
Metolazone—CA5B—Metabolism—AQP1—nephrolithiasis	4.85e-05	0.00388	CbGpPWpGaD
Metolazone—CA7—Metabolism—AQP1—nephrolithiasis	4.85e-05	0.00388	CbGpPWpGaD
Metolazone—CA9—Metabolism—AGXT—nephrolithiasis	4.78e-05	0.00383	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CHRM3—nephrolithiasis	4.69e-05	0.00376	CbGpPWpGaD
Metolazone—CA12—Metabolism—AQP1—nephrolithiasis	4.49e-05	0.0036	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CHRM3—nephrolithiasis	4.38e-05	0.00351	CbGpPWpGaD
Metolazone—CA7—Metabolism—CHRM3—nephrolithiasis	4.38e-05	0.00351	CbGpPWpGaD
Metolazone—CA9—Metabolism—SLC26A1—nephrolithiasis	4.06e-05	0.00325	CbGpPWpGaD
Metolazone—CA12—Metabolism—CHRM3—nephrolithiasis	4.06e-05	0.00325	CbGpPWpGaD
Metolazone—CA9—Metabolism—APRT—nephrolithiasis	4.06e-05	0.00325	CbGpPWpGaD
Metolazone—CA4—Metabolism—AQP1—nephrolithiasis	3.58e-05	0.00287	CbGpPWpGaD
Metolazone—CA4—Metabolism—CHRM3—nephrolithiasis	3.24e-05	0.00259	CbGpPWpGaD
Metolazone—CA9—Metabolism—AQP1—nephrolithiasis	2.89e-05	0.00232	CbGpPWpGaD
Metolazone—CA9—Metabolism—CHRM3—nephrolithiasis	2.62e-05	0.0021	CbGpPWpGaD
